Diabetes
We recommend
How Does Empagliflozin Stand in Terms of Diabetic Retinopathy Risk? We Have Answers Not Only from Controlled Studies but Also from Real Practice
Modern antidiabetics – gliflozins and glucagon-like peptide-1 receptor agonists (GLP-1RA) – significantly help improve the management of type 2 diabetes (DM2). In addition to reliable glycemic control, they offer other benefits. For example, gliflozins are known for their cardio- and renoprotective properties. GLP-1RA also reduce cardiovascular (CV) risk, though clinical evaluation (SUSTAIN-6) suggests a possible higher risk of retinopathy. This is also being investigated with gliflozins. How empagliflozin fares in this respect has been…
The Significance of Administering Gliflozins in Real Practice in Diabetics Without CV and Renal Disease
Current care standards recommend the use of sodium-glucose cotransporter 2 inhibitors (SGLT2i,…
Benefit of Empagliflozin in Patients with Chronic Kidney Disease – Results of the EMPA-KIDNEY Study
The sodium-glucose cotransporter 2 inhibitor (SGLT2i) empagliflozin is currently used to treat type…
Articles on this topic
Early Detection of Erectile Dysfunction in Men with Type 2 Diabetes
A retrospective study published last year identified predictors of erectile dysfunction in men…
Is it possible to extend the life of diabetics thanks to modern treatment?
People aged 60 with type 2 diabetes are estimated to live on average 6-7 years less compared…
Comparison of Cardiovascular Effects of Sitagliptin and Empagliflozin
Cardiovascular (CV) diseases remain the leading cause of death among patients with type 2…
Albuminuria as a Risk Factor for Cardiovascular Events and Mortality in Patients with Type 2 Diabetes Without Apparent Cardiovascular Disease
Albuminuria in patients with type 2 diabetes is associated with a higher risk of…
How Diabetes Shortens Life or Mortality of Patients with Type 2 Diabetes
Type 2 diabetes mellitus (DM) has a significant impact on overall mortality across age…
Diabetic Cardiovascular Autonomic Neuropathy: How to Detect This Serious Diagnosis and Why Is It Dangerous?
Diabetic autonomic neuropathy can affect various organ systems. Cardiovascular autonomic…
New Antidiabetic Drugs in Cardiovascular Prevention in International Recommendations
Results from studies on new antidiabetic drugs showing cardiovascular (CV) benefits of…
Effect of Empagliflozin on Clinical Stability in Patients with Heart Failure and Reduced LV Ejection Fraction
Previous studies have shown that the oral antidiabetic drug empagliflozin reduces the risk of…
Overlap of SGLT2 Inhibitors from Diabetology to Cardiology
As recent research shows, one of the modern groups of antidiabetic drugs - SGLT2 inhibitors,…
Reducing Cardiovascular Risk in Diabetics Through Hypertension Treatment
The presence of hypertension in patients with diabetes worsens overall cardiovascular (CV)…
Subscribe
Most read on this topic
Journal on this topic
Related topic
Most read on this topic
- 10 Properties and Benefits of Gliptins: How They Work and When to Prescribe Them
- Gliflozins in the Treatment of Type 2 Diabetes According to Current Recommendations SVL
- Prescription Restrictions on Antidiabetics Authorized for Prescription by General Practitioners - Status as of October 2020
- How Diabetes Shortens Life or Mortality of Patients with Type 2 Diabetes
- Mechanisms Connecting Diabetes Mellitus and Obesity
- What a General Practitioner Needs to Know About Gliflozins
Journal on this topic
Related topic